Echo Therapeutics (ECTE) Income Statement

Click line-items for a historical chart and %

Income Statement [Abstract]
Licensing revenue	0
Other revenue
Total revenues	0
Operating Expenses:
Research and development	588.55K
Selling, general and administrative	1.2M
Total operating expenses	1.81M
Loss from operations	-1.81M
Other Income (Expense):
Interest income
Interest expense	-133.06K
Qualified therapeutic research grant
Gain (loss) on extinguishment of debt/payables
Gain (loss) on disposal of assets
Derivative warrant liability gain (loss)	3.68M
Other income (expense), net	2.61M
Net loss	794.17K
Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock
Deemed dividend on warrant repricings
Accretion of dividends on Convertible Perpetual Redeemable Preferred Stock
Net loss applicable to common shareholders	794.17K
Net loss per common share, basic and diluted
Basic and diluted weighted average common shares outstanding

Entities mentioned with ECTE